Brief: Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism
04/02/2026 13:07
Feb 4 (Reuters) - Entera Bio Ltd 5DT.F: OPKO HEALTH AND ENTERA BIO EXPAND PARTNERSHIP TO ADVANCE FIRST-IN-CLASS ORAL LONG ACTING PTH TABLET FOR PATIENTS WITH HYPOPARATHYROIDISM Source text: ID:nGNX30wmGy Further company coverage: 5DT.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement